Exploring the Interaction of Biotinylated FcGamma RI and IgG1 Monoclonal Antibodies on Streptavidin-Coated Plasmonic Sensor Chips for Label-Free VEGF Detection
Biosensors · 20.12.2024 · 14 (12) · 634
DOI: 10.3390/bios14120634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors, online erschienen am 20.12.2024. Verfasst von Soodeh Salimi Khaligh und 3 weiteren Autor:innen. Beteiligte Einrichtung: SUNUM Nanotechnology Research and Application Centre, Sabanci University, Istanbul 34956, Türkiye. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Biotin, Immunoglobulin G, Receptors, IgG. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Vascular endothelial growth factor (VEGF) is a critical angiogenesis biomarker associated with various pathological conditions, including cancer. This study leverages pre-biotinylated FcγRI interactions with IgG1-type monoclonal antibodies to develop a sensitive VEGF detection method. Utilizing surface plasmon resonance (SPR) technology, we characterized the binding dynamics of immobilized biotinylated FcγRI to an IgG1-type antibody, Bevacizumab (AVT), through kinetic studies and investigated suitable conditions for sensor surface regeneration. Subsequently, we characterized the binding of FcγRI-captured AVT to VEGF, calculating kinetic constants and binding affinity. A calibration curve was established to analyze the VEGF quantification capacity and accuracy of the biosensor, computing the limits of blank, detection, and quantification at a 95% confidence interval. Additionally, the specificity of the biosensor for VEGF over other protein analytes was assessed. This innovative biomimetic approach enabled FcγRI-mediated site-specific AVT capture, establishing a stable and reusable platform for detecting and accurately quantifying VEGF. The results indicate the effectiveness of the plasmonic sensor platform for VEGF detection, making it suitable for research applications and, potentially, clinical diagnostics. Utilizing FcγRI-IgG1 antibody binding, this study highlights the industrial and clinical value of advanced biosensing technologies, offering insights to enhance therapeutic monitoring and improve outcomes in anti-VEGF therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SUNUM Nanotechnology Research and Application Centre, Sabanci University, Istanbul 34956, Türkiye.
- Department of Bioengineering, Royal School of Mines, Imperial College London, London SW7 2AZ, UK.
ORCID-Profile: Soodeh Salimi Khaligh, Fahd Khalid-Salako, Hasan Kurt, Meral Yüce
Zitieren
APA
Khaligh, S. S., Khalid-Salako, F., Kurt, H., & Yüce, M. (2024). Exploring the Interaction of Biotinylated FcGamma RI and IgG1 Monoclonal Antibodies on Streptavidin-Coated Plasmonic Sensor Chips for Label-Free VEGF Detection. Biosensors, 14(12), 634. https://doi.org/10.3390/bios14120634
Vancouver
Khaligh SS, Khalid-Salako F, Kurt H, Yüce M. Exploring the Interaction of Biotinylated FcGamma RI and IgG1 Monoclonal Antibodies on Streptavidin-Coated Plasmonic Sensor Chips for Label-Free VEGF Detection. Biosensors. 2024;14(12):634. doi:10.3390/bios14120634
BibTeX
@article{Khaligh2024,
author = {Khaligh, Soodeh Salimi and Khalid-Salako, Fahd and Kurt, Hasan and Yüce, Meral},
title = {Exploring the Interaction of Biotinylated FcGamma RI and IgG1 Monoclonal Antibodies on Streptavidin-Coated Plasmonic Sensor Chips for Label-Free VEGF Detection},
journal = {Biosensors},
year = {2024},
volume = {14},
number = {12},
pages = {634},
doi = {10.3390/bios14120634}
}
EUVIMED